| Name | Title | Contact Details |
|---|
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen, a first-in-class anti-cancer peptide-drug conjugate that rapidly delivers an alkylating payload into tumor cells. Melflufen is in development as a new treatment for the hematological cancer multiple myeloma and is currently being evaluated in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study. Oncopeptides` headquarters is in Stockholm, Sweden with U.S. headquarters in Boston, Mass. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.
Mustang Bio, Inc., a subsidiary of Fortress Biotech, Inc., is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient`s own immune system to eliminate cancer cells. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding research and development, and out-licensing or bringing the technologies to market. Mustang has partnered with the City of Hope National Medical Center (“COH”) and Fred Hutchinson Cancer Research Center in the development of proprietary chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies across many cancers. Mustang`s lead programs are in Phase 1 clinical trials at COH: MB-101 for the treatment of brain cancer and MB-102 as a therapeutic agent in acute myeloid leukemia.
Biosynexus understands that bringing a new pharmaceutical product to market is a complicated process that involves not only having strong research and development capabilities, but also having deep clinical development, manufacturing and marketing
At Advanced Orthopedics of Oklahoma, our specialty-trained orthopedic doctors and staff deliver the expert, compassionate care needed to heal, recover, and advance throughout Oklahoma in Tulsa, Claremore, Bixby, McAlester.
MNPHARM SBC is a manufacturer of recombinant regenerative proteins using a proprietary method called molecular farming. We supply these proteins to researchers working on therapeutic development. Our plant based expression method only takes 6 to 8 days. We offer faster production and lower cost resulting in rapid therapeutic development.